Palatin Initiates Hypertension Study

Armen Hareyan's picture
Advertisement

Palatin Technologies has initiated dosing in a Phase 2a clinical study of PL-3994, a novel, long-acting natriuretic peptide receptor A agonist, in subjects with controlled hypertension.

Advertisement